Italia markets closed

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,3650-0,0450 (-3,19%)
Alla chiusura: 04:00PM EDT
1,3694 +0,00 (+0,32%)
Dopo ore: 07:28PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,4100
Aperto1,4000
Denaro1,3500 x 100
Lettera1,4000 x 100
Min-Max giorno1,3150 - 1,4400
Intervallo di 52 settimane1,3030 - 5,1200
Volume261.676
Media Volume261.312
Capitalizzazione66,398M
Beta (5 anni mensile)2,01
Rapporto PE (ttm)N/D
EPS (ttm)-1,1100
Prossima data utili07 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A9,40
  • GlobeNewswire

    Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

    BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today two poster presentations highlighting the company’s Immuno-STAT™ platform and lead clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer’s 38th Anniversar

  • GlobeNewswire

    Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

    Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line (1L) refractory/metastatic HPV+ Head and Neck Cancer patientsData to date from CUE-101 in combination with pembrolizumab demonstrates more than double the historical ORR of pembrolizumab alone, including patients with tumors of low PD-L1 expressionUpdated data from both the combination and monotherapy trials will be presented at the 2023 Society for I

  • GlobeNewswire

    Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

    BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and financial update for the second quarter 2023. Recent Business Highlights Presented positive data update from ongoing Phase 1 trials of CUE-101 for recurrent/metastatic HPV+ head and neck squamous cell carcinoma